Coherus Oncology
CHRS
111 hedge funds and large institutions have $595M invested in Coherus Oncology in 2018 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 40 increasing their positions, 31 reducing their positions, and 23 closing their positions.
29% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 31
2.81% more ownership
Funds ownership: 93.79% → 96.6% (+2.8%)
2% more funds holding
Funds holding: 109 → 111 (+2)
9% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 23
36% less call options, than puts
Call options by funds: $531K | Put options by funds: $833K
43% less capital invested
Capital invested by funds: $1.05B → $595M (-$455M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$28M |
| 2 |
CC
Carlson Capital
Dallas,
Texas
|
+$19.9M |
| 3 |
JP Morgan Chase
New York
|
+$17.9M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$8.1M |
| 5 |
State Street
Boston,
Massachusetts
|
+$5.37M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$28.4M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$21.8M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$11.6M |
| 4 |
Millennium Management
New York
|
-$8.52M |
| 5 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$5.83M |
CHRS Hedge Fund Activity: Q4 2018 in Review
111 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q4 2018, worth a combined $595M — down 43% from $1.05B a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new CHRS positions and 23 closed out — a net gain of 2 holders — while 40 added to existing stakes and 31 trimmed.
The largest buyer was Rubric Capital Management (New York), adding an estimated $28M. The largest seller was OrbiMed, exiting entirely with an estimated $28.4M sold.
- 111 institutional investors held Coherus Oncology (CHRS) as of Q4 2018, up from 109 in Q3 2018.
- Funds reported $595M of Coherus Oncology stock for Q4 2018, down 43% quarter-over-quarter.
- 25 funds opened new Coherus Oncology positions in Q4 2018 and 23 closed out, a net change of +2 holders.
- The largest Coherus Oncology buyer in Q4 2018 was Rubric Capital Management (New York), an estimated $28M added.
- The largest Coherus Oncology seller in Q4 2018 was OrbiMed, an estimated $28.4M sold.
Based on aggregated 13F filings for Q4 2018.